IBRX
ImmunityBio, Inc.
Key Financials
Net Income
$-351398000
↑ 15.0%
Revenue
$113.3M
↑ 668.3%
Total Liabilities
$1.0B
↑ 15.0%
Cash & Equivalents
$88.3M
↓ 38.4%
Shareholders' Equity
$-500469000.00
↓ 2.3%
Operating Income
$-256027000
↑ 25.6%
EPS (Diluted)
$-0.38
↑ 38.7%
Total Assets
$501.9M
↑ 31.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/18/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| 8-K | 4/9/2026 | View on SEC |
| 8-K | 4/6/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 8-K | 3/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IBRX |
| Company Name | ImmunityBio, Inc. |
| CIK | 1326110 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (844) 696-5235 |